Limits...
Combined Efficacy of Gallic Acid and MiADMSA with Limited Beneficial Effects Over MiADMSA Against Arsenic-induced Oxidative Stress in Mouse.

Pachauri V, Flora S - Biochem Insights (2015)

Bottom Line: The study suggests that (1) gallic acid in presence of MiADMSA is only moderately beneficial against arsenic, (2) monotherapy with gallic acid is more effective than in combination with MiADMSA after arsenic exposure in reducing oxidative injury, and (3) MiADMSA monotherapy as reported previously provides significant therapeutic efficacy against arsenic.Thus, based on the present results, we conclude that gallic acid is effective against arsenic-induced oxidative stress but provides limited additional beneficial effects when administered in combination with MiADMSA.We still recommend that lower doses of gallic acid be evaluated both individually and in combination with MiADMSA, as it might not exhibit the shortcomings we observed with higher doses in this study.

View Article: PubMed Central - PubMed

Affiliation: Division of Regulatory Toxicology, Defence Research and Development Establishment, Gwalior, India.

ABSTRACT
Gallic acid is an organic acid known for its antioxidant and anticancer properties. The present study is focused on evaluating the role of gallic acid in providing better therapeutic outcomes against arsenic-induced toxicity. Animals pre-exposed to arsenic were treated with monoisoamyl meso-2,3-dimercaptosuccinic acid (MiADMSA), a new chelating drug, alone and in combination with gallic acid, consecutively for 10 days. The study suggests that (1) gallic acid in presence of MiADMSA is only moderately beneficial against arsenic, (2) monotherapy with gallic acid is more effective than in combination with MiADMSA after arsenic exposure in reducing oxidative injury, and (3) MiADMSA monotherapy as reported previously provides significant therapeutic efficacy against arsenic. Thus, based on the present results, we conclude that gallic acid is effective against arsenic-induced oxidative stress but provides limited additional beneficial effects when administered in combination with MiADMSA. We still recommend that lower doses of gallic acid be evaluated both individually and in combination with MiADMSA, as it might not exhibit the shortcomings we observed with higher doses in this study.

No MeSH data available.


Related in: MedlinePlus

Effect of MiADMSA alone or in combination with gallic acid on liver ROS, GSH, and TBARS levels in arsenic exposed mice. Groups: 1, control (no treatment); 2, MiADMSA; 3, gallic acid; 4, arsenic; 5, arsenic + MiADMSA; 6, arsenic + gallic acid; 7, arsenic + gallic acid + MiADMSA.Notes: Values are mean ± SE; n = 8. *,†,‡Values with matching symbol notations in each graph are not statistically significant at 5% level of probability.Abbreviations and units: ROS, reactive oxygen species (in fluorescence intensity units); GSH, reduced glutathione levels (in mg/g tissue weight); TBARS, thiobarbituric reactive substances (in nmoles of TBARS/g of tissue).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4552275&req=5

f4-bci-8-2015-001: Effect of MiADMSA alone or in combination with gallic acid on liver ROS, GSH, and TBARS levels in arsenic exposed mice. Groups: 1, control (no treatment); 2, MiADMSA; 3, gallic acid; 4, arsenic; 5, arsenic + MiADMSA; 6, arsenic + gallic acid; 7, arsenic + gallic acid + MiADMSA.Notes: Values are mean ± SE; n = 8. *,†,‡Values with matching symbol notations in each graph are not statistically significant at 5% level of probability.Abbreviations and units: ROS, reactive oxygen species (in fluorescence intensity units); GSH, reduced glutathione levels (in mg/g tissue weight); TBARS, thiobarbituric reactive substances (in nmoles of TBARS/g of tissue).

Mentions: Liver ROS increased significantly on arsenic exposure, and it remained unchanged on treatment with gallic acid and MiADMSA either alone or in combination. Liver GSH, on the other hand, increased on arsenic exposure but responded favorably to monotherapy with MiADMSA (Fig. 4). Interestingly, liver TBARS, which increased on arsenic exposure, showed further elevation on combined treatment with MiADMSA and gallic acid.


Combined Efficacy of Gallic Acid and MiADMSA with Limited Beneficial Effects Over MiADMSA Against Arsenic-induced Oxidative Stress in Mouse.

Pachauri V, Flora S - Biochem Insights (2015)

Effect of MiADMSA alone or in combination with gallic acid on liver ROS, GSH, and TBARS levels in arsenic exposed mice. Groups: 1, control (no treatment); 2, MiADMSA; 3, gallic acid; 4, arsenic; 5, arsenic + MiADMSA; 6, arsenic + gallic acid; 7, arsenic + gallic acid + MiADMSA.Notes: Values are mean ± SE; n = 8. *,†,‡Values with matching symbol notations in each graph are not statistically significant at 5% level of probability.Abbreviations and units: ROS, reactive oxygen species (in fluorescence intensity units); GSH, reduced glutathione levels (in mg/g tissue weight); TBARS, thiobarbituric reactive substances (in nmoles of TBARS/g of tissue).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4552275&req=5

f4-bci-8-2015-001: Effect of MiADMSA alone or in combination with gallic acid on liver ROS, GSH, and TBARS levels in arsenic exposed mice. Groups: 1, control (no treatment); 2, MiADMSA; 3, gallic acid; 4, arsenic; 5, arsenic + MiADMSA; 6, arsenic + gallic acid; 7, arsenic + gallic acid + MiADMSA.Notes: Values are mean ± SE; n = 8. *,†,‡Values with matching symbol notations in each graph are not statistically significant at 5% level of probability.Abbreviations and units: ROS, reactive oxygen species (in fluorescence intensity units); GSH, reduced glutathione levels (in mg/g tissue weight); TBARS, thiobarbituric reactive substances (in nmoles of TBARS/g of tissue).
Mentions: Liver ROS increased significantly on arsenic exposure, and it remained unchanged on treatment with gallic acid and MiADMSA either alone or in combination. Liver GSH, on the other hand, increased on arsenic exposure but responded favorably to monotherapy with MiADMSA (Fig. 4). Interestingly, liver TBARS, which increased on arsenic exposure, showed further elevation on combined treatment with MiADMSA and gallic acid.

Bottom Line: The study suggests that (1) gallic acid in presence of MiADMSA is only moderately beneficial against arsenic, (2) monotherapy with gallic acid is more effective than in combination with MiADMSA after arsenic exposure in reducing oxidative injury, and (3) MiADMSA monotherapy as reported previously provides significant therapeutic efficacy against arsenic.Thus, based on the present results, we conclude that gallic acid is effective against arsenic-induced oxidative stress but provides limited additional beneficial effects when administered in combination with MiADMSA.We still recommend that lower doses of gallic acid be evaluated both individually and in combination with MiADMSA, as it might not exhibit the shortcomings we observed with higher doses in this study.

View Article: PubMed Central - PubMed

Affiliation: Division of Regulatory Toxicology, Defence Research and Development Establishment, Gwalior, India.

ABSTRACT
Gallic acid is an organic acid known for its antioxidant and anticancer properties. The present study is focused on evaluating the role of gallic acid in providing better therapeutic outcomes against arsenic-induced toxicity. Animals pre-exposed to arsenic were treated with monoisoamyl meso-2,3-dimercaptosuccinic acid (MiADMSA), a new chelating drug, alone and in combination with gallic acid, consecutively for 10 days. The study suggests that (1) gallic acid in presence of MiADMSA is only moderately beneficial against arsenic, (2) monotherapy with gallic acid is more effective than in combination with MiADMSA after arsenic exposure in reducing oxidative injury, and (3) MiADMSA monotherapy as reported previously provides significant therapeutic efficacy against arsenic. Thus, based on the present results, we conclude that gallic acid is effective against arsenic-induced oxidative stress but provides limited additional beneficial effects when administered in combination with MiADMSA. We still recommend that lower doses of gallic acid be evaluated both individually and in combination with MiADMSA, as it might not exhibit the shortcomings we observed with higher doses in this study.

No MeSH data available.


Related in: MedlinePlus